NEWS
Paul Hastings Advises on Mediation and Related Agreement in Life Sciences Sector
November 17, 2025
Paul Hastings LLP advised on a successful mediation and related agreement in the life sciences sector, drawing on an integrated team of lawyers in life sciences transactions and international arbitration. The firm advised Orchestra BioMed Holdings Inc., (Nasdaq: OBIO), a U.S.-based biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships. The mediation procedure led to a new agreement with Terumo Corporation and Terumo Medical Corporation of Japan (collectively, Terumo) in connection with Orchestra BioMed’s Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), for the treatment of coronary artery disease worldwide.
As a result of the mediation procedure under international rules, the parties reached a new agreement that grants Terumo a right of first refusal to acquire the rights, or enter a distribution arrangement, with respect to Virtue SAB in exchange for an upfront payment of $10 million. Orchestra BioMed and Terumo have also entered into a securities purchase agreement, pursuant to which Terumo invested an additional $20 million in Orchestra BioMed through a new series of nonvoting preferred stock convertible into common stock in the future, subject to certain conditions.
The Paul Hastings team included Sam Waxman, Jonathan C. Hamilton, Jonathan Ulrich, Yariv Katz and Keith Pisani.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.